Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02834247 · ClinicalTrials.gov registry record · Phase 1
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by Calithera Biosciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT02834247 is a Phase 1 study that was terminated before completion, run by Calithera Biosciences. The registered enrollment target is 41 participants.
The verdict
NCT02834247, a Phase 1 study, was terminated before completion, sponsored by Calithera Biosciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
Interventions
- DRUG Nivolumab
- DRUG TAK-659
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2016-08-12 |
| Est. Completion | 2018-11-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02834247
The ClinicalTrials.gov registry entry for NCT02834247 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Calithera Biosciences, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT02834247 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02834247 about?
NCT02834247 is a clinical study titled "A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors". The purpose of this study is to evaluate the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D), safety and efficacy of TAK-659 in combination with nivolumab in participants with advanced solid tumors.
What is the current status of trial NCT02834247?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2016-08-12. Estimated completion is 2018-11-30.
What interventions are being tested in trial NCT02834247?
The interventions under investigation include: Nivolumab (DRUG), TAK-659 (DRUG).
Who is sponsoring clinical trial NCT02834247?
This trial is sponsored by Calithera Biosciences, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.